Sanofi Investors Might Have to Wait for Update on Strategy -- Market Talk

Dow Jones04-10 19:12

1111 GMT - Sanofi will provide little commentary about strategic priorities at its first-quarter results later this month since new CEO Belen Garijo won't start until shortly afterward, UBS analysts say in a research note. The French drugmaker's results are likely to be positive, but any strategic update will be limited, the analysts say. "Prior management comments suggested the potential for a refocus on the Regeneron [joint venture] for future drug launches but we assume it is too early to explore this potential." Recent drug-pipeline disappointments have made many investors lukewarm on Sanofi, but its steady growth in the near and medium term might attract some, UBS says. Shares rise 0.3%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 10, 2026 07:12 ET (11:12 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626696194?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626696194","market":"fut","top_or_hot":-1,"title":"Sanofi Investors Might Have to Wait for Update on Strategy -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1111 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> will provide little commentary about strategic priorities at its first-quarter results later this month since new CEO Belen Garijo won't start until shortly afterward, UBS analysts say in a research note. The French drugmaker's results are likely to be positive, but any strategic update will be limited, the analysts say. \"Prior management comments suggested the potential for a refocus on the Regeneron [joint venture] for future drug launches but we assume it is too early to explore this potential.\" Recent drug-pipeline disappointments have made many investors lukewarm on <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a>, but its steady growth in the near and medium term might attract some, UBS says. Shares rise 0.3%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 07:12 ET (11:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Investors Might Have to Wait for Update on Strategy -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Investors Might Have to Wait for Update on Strategy -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-10 19:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1111 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> will provide little commentary about strategic priorities at its first-quarter results later this month since new CEO Belen Garijo won't start until shortly afterward, UBS analysts say in a research note. The French drugmaker's results are likely to be positive, but any strategic update will be limited, the analysts say. \"Prior management comments suggested the potential for a refocus on the Regeneron [joint venture] for future drug launches but we assume it is too early to explore this potential.\" Recent drug-pipeline disappointments have made many investors lukewarm on <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a>, but its steady growth in the near and medium term might attract some, UBS says. Shares rise 0.3%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 07:12 ET (11:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2626696194","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626696194","pubTimestamp":1775819520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1111 GMT - Sanofi will provide little commentary about strategic priorities at its first-quarter results later this month since new CEO Belen Garijo won't start until shortly afterward, UBS analysts say in a research note. The French drugmaker's results are likely to be positive, but any strategic update will be limited, the analysts say. \"Prior management comments suggested the potential for a refocus on the Regeneron [joint venture] for future drug launches but we assume it is too early to explore this potential.\" Recent drug-pipeline disappointments have made many investors lukewarm on Sanofi, but its steady growth in the near and medium term might attract some, UBS says. Shares rise 0.3%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","BK4588":"碎股","ISBC":"投资者银行","BK4585":"ETF&股票定投概念","SNYNF":"Sanofi","SNY":"赛诺菲安万特","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4007":"制药"},"translate_title":"赛诺菲投资者可能需要等待战略更新——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1.5,"SNY":0.9,"ISBC":1.5},"content_text":"1111 GMT - Sanofi will provide little commentary about strategic priorities at its first-quarter results later this month since new CEO Belen Garijo won't start until shortly afterward, UBS analysts say in a research note. The French drugmaker's results are likely to be positive, but any strategic update will be limited, the analysts say. \"Prior management comments suggested the potential for a refocus on the Regeneron [joint venture] for future drug launches but we assume it is too early to explore this potential.\" Recent drug-pipeline disappointments have made many investors lukewarm on Sanofi, but its steady growth in the near and medium term might attract some, UBS says. Shares rise 0.3%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2026 07:12 ET (11:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626696194","isCrawlerRequest":true}